Posts Tagged ‘ASH’
Stephan Moll, MD writes... The annual American Society of Hematology (ASH) meeting took place in Dec 2014 in San Francisco. A summary of the clinically relevant thrombosis and anticoagulation presentation and abstracts is presented here (Top 10 ASH Highlights).
Disclosure: I have been a consultant to Portola, Daiichi, Janssen, and Boehringer-Ingelheim.
Last updated: Jan 27th, 2015
Stephan Moll, MD writes (Dec 17, 2014)… The American Society of Hematology (ASH) published last week as part of its Choosing Wisely® campaign two things that physicians dealing with DVT, PE and anticoagulants should avoid [ref 1]. Read the rest of this entry »
Stephan Moll, MD writes… The annual meeting of the American Society of Hematology (ASH) took place this month (Dec 6-12th, 2013) in New Orleans. The clinically relevant highlights about thrombosis and anticoagulation are summarized below. Read the rest of this entry »
Stephan Moll, MD writes… The American Society of Hematology (ASH) has identified 3 things that physicians dealing with DVT, PE and anticoagulation should avoid – published today [ref 1]. Read the rest of this entry »
The annual meeting of the American Society of Hematology (ASH) took place in San Diego from Dec 10-13, 2011. Abstracts on thrombosis and anticoagulation that I found interesting and clinically relevant are summarized and put into a clinical perspective in this summary document. Only one abstract was, in my assessment, clinical-practice-changing – abstract #543: “Aspirin after oral anticoagulants for prevention of recurrence in patients with unprovoked VTE. The WARFASA study”. It is the first abstract discussed in the summary document.
Disclosure: I have no conflict of interest relevant to this post.
Last updated: Dec 13th, 2011